Opus Genetics vs Zenas Biopharma
Opus Genetics is the larger business, with $14.2m of revenue in fiscal 2025 against $10.0m for Zenas Biopharma (1.4 times as much). Zenas Biopharma grew faster (100.0% against 29.1%). Opus Genetics kept more of each dollar of sales as profit: a net margin of -349.3% against -3777.4%. Opus Genetics carries less debt relative to equity (7.4% against 32.5%).
| Latest fiscal year | Opus GeneticsIRD, 2025 | Zenas BiopharmaZBIO, 2025 |
|---|---|---|
| Revenue | $14.2m | $10.0m |
| Revenue growth | 29.1% | 100.0% |
| Net income | −$49.6m | −$378m |
| Operating margin | -271.9% | -3830.6% |
| Net margin | -349.3% | -3777.4% |
| Return on equity | — | -136.2% |
| Free cash flow | −$35.3m | −$172m |
| Cash | $45.1m | $111m |
| Total debt | $1.1m | $78.6m |
| Debt to equity | 7.4% | 32.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 27 | 167 |
| Market value | $324m | $1.79bn |
| Price vs our value range | — | — |
| Moat score | 10 (Weak) | — |
| Insider trades, 12 months | 2 buys, 23 sales | 17 buys, 0 sales |